Author, YearID No. | Patient population | Medication treatment | Control | Patients (RCTs) | Mean agea | Outcome mean follow-upb | NNH (95% CI) RR (95% CI) | I2% | Quality of the evidencec |
---|---|---|---|---|---|---|---|---|---|
Increase hospital admissions from out-patient, day-procedure, or community settings | |||||||||
 Baigent, 20131653a | Patients indicated for NSAID treatment | COX2-inhibitors | Placebo | 88,367 (184) | Unclear | HF hospitalisation, Follow-up unclear | NNH: 3 (2 to 6) rr: 2.28 (1.62 to 3.20)d | Unclear | Moderate |
 Sampson, 20136806f | Schizophrenia | Intermittent antipsychotic therapy | Maintenance antipsychotic therapy | 661 (6) | 35 ± 5 | Hospitalisation at 21 months | NNH: 7 (4 to 15) RR: 1.58 (1.28 to 1.97) | 19 | High |
 Kew, 20144004z | Moderate to severe stable COPD | Fluticasone | Placebo | 16,338 (15) | 64 ± 1 | Pneumonia hospitalisation at 12 months | NNH: 164 (114 to 259) RR: 1.81 (1.51 to 2.17) | 0 | High |